BeOne Medicines AG (HKG:6160)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 271.65B +26.8% |
| Revenue (ttm) | 45.00B +37.4% |
| Net Income | 4.02B |
| EPS | 34.53 |
| Shares Out | n/a |
| PE Ratio | 67.54 |
| Forward PE | 44.11 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,968,123 |
| Average Volume | 3,536,996 |
| Open | 189.70 |
| Previous Close | 190.60 |
| Day's Range | 183.30 - 191.80 |
| 52-Week Range | 125.10 - 229.40 |
| Beta | 0.50 |
| RSI | 58.86 |
| Earnings Date | Apr 15, 2026 |
About BeOne Medicines AG
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients w... [Read more]
News
BeOne Medicines price target raised to $395 from $389 at Morgan Stanley
Morgan Stanley raised the firm’s price target on BeOne Medicines (ONC) to $395 from $389 and keeps an Overweight rating on the shares.
BeOne Medicines price target raised to $409 from $405 at Barclays
Barclays raised the firm’s price target on BeOne Medicines (ONC) to $409 from $405 and keeps an Overweight rating on the shares.
BeOne Medicines price target raised to $420 from $410 at Guggenheim
Guggenheim analyst Michael Schmidt raised the firm’s price target on BeOne Medicines (ONC) to $420 from $410 and keeps a Buy rating on the shares after the company reported a
Q1 2026 BeOne Medicines AG Earnings Call Transcript
Q1 2026 BeOne Medicines AG Earnings Call Transcript
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
Business Wire India Total global revenues of $1.5 billion for the first quarter, an increase of 35% from the prior year Foundational BRUKINSA (zanubrutinib) global revenues of $1.1 billion for…
BeOne Medicines AG Earnings Call Transcript: Q1 2026
Q1 2026 saw robust revenue and earnings growth, driven by strong performance in hematology and solid tumor franchises. Full-year revenue guidance was raised by $100 million, with continued margin expansion and pipeline progress across key programs.
BeOne Medicines Announces First Quarter 2026 Financial Results and Business Updates
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates fr...
BeOne Medicines initiated with an Overweight at Wells Fargo
Wells Fargo analyst Yanan Zhu initiated coverage of BeOne Medicines (ONC) with an Overweight rating and $400 price target The firm believes the company is well positioned in the $12B
BeOne Medicines (ONC) Receives FDA Priority Review for Tevimbra Treatment
BeOne Medicines (ONC) Receives FDA Priority Review for Tevimbra Treatment
BeOne Medicines: FDA grants Priority Review to sBLA for tevimbra/ziihera combo
BeOne Medicines (ONC) announced that the U.S. FDA has granted Priority Review to a supplemental Biologics License Application for tevimbra in combination with ziihera and chemotherapy for the first-li...
U.S. FDA Grants Priority Review to BeOne Medicines' TEVIMBRA in First-Line HER2+ GEA
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration...
BeOne Medicines to Announce First Quarter 2026 Financial Results on May 6
SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its first quarter 2026 financial results on We...
Baker Bros. Advisors LP's Strategic Acquisition of BeOne Medicines Ltd Shares
Baker Bros. Advisors LP's Strategic Acquisition of BeOne Medicines Ltd Shares
BeiGene Acquires Exclusive Rights for Fizepizumab in Greater China
BeiGene Acquires Exclusive Rights for Fizepizumab in Greater China
BeiGene (ONC) Prepares for Q1 Earnings Announcement with Strong Track Record
BeiGene (ONC) Prepares for Q1 Earnings Announcement with Strong Track Record
BeOne Medicines (ONC) Receives Conditional Approval for Lung Cancer Treatment
BeOne Medicines (ONC) Receives Conditional Approval for Lung Cancer Treatment
BeOne Medicines price target lowered to $411 from $412 at Truist
Truist lowered the firm’s price target on BeOne Medicines (ONC) to $411 from $412 and keeps a Buy rating on the shares as part of a broader research note previewing
BeOne Medicines initiated with an Outperform at Wolfe Research
Wolfe Research analyst Kalpit Patel initiated coverage of BeOne Medicines (ONC) with an Outperform rating and $340 price target The company “seems to run one of the broadest development programs
BeOne Medicines downgraded to Hold from Buy at Jefferies
Jefferies analyst Faisal Khurshid downgraded BeOne Medicines (ONC) to Hold from Buy with a price target of $290, down from $420, after assuming coverage of the name. The company’s Brukinsa
BeOne Medicines AG Transcript: TD Cowen 46th Annual Health Care Conference
Revenue guidance for 2026 is $6.2–$6.4 billion, driven by global growth and strong product performance. Multiple pipeline assets are advancing, with key data readouts and registrational studies planned for 2024–2026. Hematology assets show strong differentiation and market expansion potential.
BeOne Medicines price target raised to $412 from $400 at Truist
Truist analyst Gregory Renza raised the firm’s price target on BeOne Medicines (ONC) to $412 from $400 and keeps a Buy rating on the shares after its Q4 results. The
BeOne Medicines price target raised to $425 from $417 at RBC Capital
RBC Capital analyst Leonid Timashev raised the firm’s price target on BeOne Medicines (ONC) to $425 from $417 and keeps an Outperform rating on the shares. The company reported its
BeOne Medicines price target raised to $410 from $400 at Guggenheim
Guggenheim raised the firm’s price target on BeOne Medicines (ONC) to $410 from $400 and keeps a Buy rating on the shares after updating the firm’s model to reflect Q4
BeOne Medicines price target raised to $405 from $394 at Barclays
Barclays analyst Etzer Darout raised the firm’s price target on BeOne Medicines (ONC) to $405 from $394 and keeps an Overweight rating on the shares post the Q4 report. The
BeOne Medicines AG Earnings Call Transcript: Q4 2025
Delivered strong 2025 results with 49% BRUKINSA revenue growth, GAAP profitability, and robust cash flow. 2026 guidance projects $6.2–$6.4 billion revenue, driven by continued BTK leadership and new launches. R&D pipeline advanced with multiple Phase III studies and global approvals.